Central CRF system perturbation in an Alzheimer's disease knockin mouse model

Neurobiology of Aging

Volumn 33, Issue 11, 2012, Pages 2678-2691

  Guo, Qinxi ^a   Zheng, Hui ^a   Justice, Nicholas John ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Anxiety; APP; Corticosteroids; Corticotropin releasing factor; CRF; CRFR1; CRH; CRHR1; Depression; HPA axis; Presenilin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CORTICOSTEROID; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; FEAR; HETEROZYGOSITY; HOT PLATE TEST; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS NUCLEUS; IMMUNOHISTOCHEMISTRY; LIGHT DARK CYCLE; LIMBIC CORTEX; MAZE TEST; MEMORY DISORDER; MESENCEPHALON; MOUSE; MUTATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WORKING MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANXIETY; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HUMANS; MICE; PITUITARY-ADRENAL SYSTEM; PRESENILIN-1; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 84865600134     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.01.002     Document Type: Article

References (72)

1. Arendash G.W., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E., Diamond D.M. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 2001, 891:42-53.
2. Ayensu W.K., Pucilowski O., Mason G.A., Overstreet D.H., Rezvani A.H., Janowsky D.S. Effects of chronic mild stress on serum complement activity, saccharin preference, and corticosterone levels in Flinders lines of rats. Physiol. Behav 1995, 57:165-169.
3. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013.
4. Bourin M., Hascoët M. The mouse light/dark box test. Eur. J. Pharmacol 2003, 463:55-65.
5. Boy J., Leergaard T.B., Schmidt T., Odeh F., Bichelmeier U., Nuber S., Holzmann C., Wree A., Prusiner S.B., Bujard H., Riess O., Bjaalie J.G. Expression mapping of tetracycline-responsive prion protein promoter: digital atlasing for generating cell-specific disease models. Neuroimage 2006, 33:449-462.
6. Budas G., Coughlan C.M., Seckl J.R., Breen K.C. The effect of corticosteroids on amyloid beta precursor protein/amyloid precursor-like protein expression and processing in vivo. Neurosci. Lett 1999, 276:61-64.
7. Card J.P., Meade R.P., Davis L.G. Immunocytochemical localization of the precursor protein for beta-amyloid in the rat central nervous system. Neuron 1988, 1:835-846.
8. Catania C., Sotiropoulos I., Silva R., Onofri C., Breen K.C., Sousa N., Almeida O.F. The amyloidogenic potential and behavioral correlates of stress. Mol. Psychiatry 2009, 14:95-105.
9. Csernansky J.G., Dong H., Fagan A.M., Wang L., Xiong C., Holtzman D.M., Morris J.C. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am. J. Psychiatry 2006, 163:2164-2169.
10. Davis K.L., Davis B.M., Greenwald B.S., Mohs R.C., Mathé A.A., Johns C.A., Horvath T.B. Cortisol and Alzheimer's disease, I: Basal studies. Am. J. Psychiatry 1986, 143:300-305.
11. Deacon R.M., Rawlins J.N. T-maze alternation in the rodent. Nat. Protoc 2006, 1:7-12.
12. Dong H., Goico B., Martin M., Csernansky C.A., Bertchume A., Csernansky J.G. Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 2004, 127:601-609.
13. Dong H., Yuede C.M., Yoo H.S., Martin M.V., Deal C., Mace A.G., Csernansky J.G. Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. Neuroscience 2008, 155:154-163.
14. Feldman H., Scheltens P., Scarpini E., Hermann N., Mesenbrink P., Mancione L., Tekin S., Lane R., Ferris S. Behavioral symptoms in mild cognitive impairment. Neurology 2004, 62:1199-1201.
15. Flood D.G., Reaume A.G., Dorfman K.S., Lin Y.G., Lang D.M., Trusko S.P., Savage M.J., Annaert W.G., De Strooper B., Siman R., Scott R.W. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol. Aging 2002, 23:335-348.
16. Freir D.B., Fedriani R., Scully D., Smith I.M., Selkoe D.J., Walsh D.M., Regan C.M. Aβ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol. Aging 2011, 32:2211-2218.
17. Gabryelewicz T., Styczynska M., Pfeffer A., Wasiak B., Barczak A., Luczywek E., Androsiuk W., Barcikowska M. Prevalence of major and minor depression in elderly persons with mild cognitive impairment-MADRS factor analysis. Int. J. Geriatr. Psychiatry 2004, 19:1168-1172.
18. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
19. Gil-Bea F.J., Aisa B., Schliebs R., Ramírez M.J. Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. Behav. Neurosci 2007, 121:340-344.
20. Green K.N., Billings L.M., Roozendaal B., McGaugh J.L., LaFerla F.M. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci 2006, 26:9047-9056.
21. Guo Q., Fu W., Sopher B.L., Miller M.W., Ware C.B., Martin G.M., Mattson M.P. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat. Med 1999, 5:101-106.
22. Harris J.A., Devidze N., Verret L., Ho K., Halabisky B., Thwin M.T., Kim D., Hamto P., Lo I., Yu G.Q., Palop J.J., Masliah E., Mucke L. Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 2010, 68:428-441.
23. Hartmann A., Veldhuis J.D., Deuschle M., Standhardt H., Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol. Aging 1997, 18:285-289.
24. Heinrichs S.C., Menzaghi F., Merlo Pich E., Britton K.T., Koob G.F. The role of CRF in behavioral aspects of stress. Ann. N. Y. Acad. Sci 1995, 771:92-104.
25. Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Weinberg G., Klockgether T., Feinstein D.L. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci 2002, 22:2434-2442.
26. Henry B., Vale W., Markou A. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J. Neurosci 2006, 26:9142-9152.
27. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
28. Jawhar S., Trawicka A., Jenneckens C., Bayer T.A., Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 2012, 33:196. e29-40.
29. Justice N.J., Yuan Z.F., Sawchenko P.E., Vale W. Type 1 corticotropin-releasing factor receptor expression reported in BAC transgenic mice: implications for reconciling ligand-receptor mismatch in the central corticotropin-releasing factor system. J. Comp. Neurol 2008, 511:479-496.
30. Kang J.E., Cirrito J.R., Dong H., Csernansky J.G., Holtzman D.M. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10673-10678.
31. Kasuga K., Ohno T., Ishihara T., Miyashita A., Kuwano R., Onodera O., Nishizawa M., Ikeuchi T. Depression and psychiatric symptoms preceding onset of dementia in a family with early-onset Alzheimer disease with a novel PSEN1 mutation. J. Neurol 2009, 256:1351-1353.
32. Köhler C., Ebert U., Baumann K., Schröder H. Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. Neurobiol. Dis 2005, 20:528-540.
33. Koob G.F., Thatcher-Briton K., Tazi A., Le Moal M. Behavioral pharmacology of stress: Focus on CNS corticotropin-releasing factor. Adv. Exp. Med. Biol 1988, 245:25-34.
34. Lalonde R., Lewis T.L., Strazielle C., Kim H., Fukuchi K. Transgenic mice expressing the betaAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination. Brain Res 2003, 977:38-45.
35. LeDoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci 2000, 23:155-184.
36. Lee K.W., Lee S.H., Kim H., Song J.S., Yang S.D., Paik S.G., Han P.L. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. J. Neurosci. Res 2004, 76:572-580.
37. Lee S., Smith G.W., Vale W., Lee K.F., Rivier C. Mice that lack corticotropin-releasing factor (CRF) receptors type 1 show a blunted ACTH response to acute alcohol despite up-regulated constitutive hypothalamic CRF gene expression. Alcohol. Clin. Exp. Res 2001, 25:427-433.
38. Li H., Wang Z., Wang B., Guo Q., Dolios G., Tabuchi K., Hammer R.E., Südhof T.C., Wang R., Zheng H. Genetic dissection of the amyloid precursor protein in developmental function and amyloid pathogenesis. J. Biol. Chem 2010, 285:30598-30605.
39. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
40. Lupien S.J., de Leon M., de Santi S., Convit A., Tarshish C., Nair N.P., Thakur M., McEwen B.S., Hauger R.L., Meaney M.J. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat. Neurosci 1998, 1:69-73.
41. Matthews K.L., Chen C.P., Esiri M.M., Keene J., Minger S.L., Francis P.T. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry 2002, 51:407-416.
42. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci 2000, 20:4050-4058.
43. Mullan M., Tsuji S., Miki T., Katsuya T., Naruse S., Kaneko K., Shimizu T., Kojima T., Nakano I., Ogihara T., et al. Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-->Ile mutation in the amyloid precursor protein gene. Neurobiol. Aging 1993, 14:407-419.
44. Ouimet C.C., Baerwald K.D., Gandy S.E., Greengard P. Immunocytochemical localization of amyloid precursor protein in rat brain. J. Comp. Neurol 1994, 348:244-260.
45. Owens M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev 1991, 43:425-473.
46. Panza F., Frisardi V., Capurso C., D'Introno A., Colacicco A.M., Imbimbo B.P., Santamato A., Vendemiale G., Seripa D., Pilotto A., Capurso A., Solfrizzi V. Late-life depression, mild cognitive impairment, and dementia: possible continuum?. Am. J. Geriatr. Psychiatry 2010, 18:98-116.
47. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
48. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., Sawchenko P., Vale W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:2969-2973.
49. Perrin M.H., Donaldson C.J., Chen R., Lewis K.A., Vale W.W. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 1993, 133:3058-3061.
50. Rissman R.A., Lee K.F., Vale W., Sawchenko P.E. Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. J. Neurosci 2007, 27:6552-6562.
51. Rothman S.M., Herdener N., Camandola S., Texel S.J., Mughal M.R., Cong W.N., Martin B., Mattson M.P. 3xTgAD mice exhibit altered behavior and elevated Aβ after chronic mild social stress. Neurobiol. Aging 2011, 2011 Aug 18. [Epub ahead of print] http://dx.doi.org/10.1016/j.neurobiolaging.2011.07.005.
52. Rozzini L., Vicini Chilovi B., Conti M., Delrio I., Borroni B., Trabucchi M., Padovani A. Neuropsychiatric symptoms in amnestic and nonamnestic mild cognitive impairment. Dement. Geriatr. Cogn. Disord 2008, 25:32-36.
53. Saper C.B. Central autonomic system. The Rat Nervous System 1995, 107-128. Academic Press, San Diego. second ed. G. Paxinos (Ed.).
54. Sapolsky R.M. Glucocorticoids, stress, and their adverse neurological effects: relevance to aging. Exp. Gerontol 1999, 34:721-732.
55. Selkoe D.J., Wolfe M.S. In search of gamma-secretase: presenilin at the cutting edge. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5690-5692.
56. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci 2007, 27:2866-2875.
57. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998, 20:1093-1102.
58. Song L., Che W., Min-Wei W., Murakami Y., Matsumoto K. Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol. Biochem. Behav 2006, 83:186-193.
59. Sterniczuk R., Antle M.C., Laferla F.M., Dyck R.H. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 2. Behavioral and cognitive changes. Brain Res 2010, 1348:149-155.
60. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13287-13292.
61. Swanson L.W., Sawchenko P.E., Rivier J., Vale W.W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 1983, 36:165-186.
62. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet 1998, 19:162-166.
63. Touma C., Ambrée O., Görtz N., Keyvani K., Lewejohann L., Palme R., Paulus W., Schwarze-Eicker K., Sachser N. Age- and sex-dependent development of adrenocortical hyperactivity in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 2004, 25:893-904.
64. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213:1394-1397.
65. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., Prins G.S., Perrin M., Vale W., Sawchenko P.E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol 2000, 428:191-212.
66. Walker D.L., Miles L.A., Davis M. Selective participation of the bed nucleus of the stria terminalis and CRF in sustained anxiety-like versus phasic fear-like responses. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1291-1308.
67. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
68. Weiner M.F., Vobach S., Olsson K., Svetlik D., Risser R.C. Cortisol secretion and Alzheimer's disease progression. Biol. Psychiatry 1997, 42:1030-1038.
69. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.
70. Yang L., Wang Z., Wang B., Justice N.J., Zheng H. Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity. J. Neurosci 2009, 29:15660-15668.
71. Zheng H., Jiang M., Trumbauer M.E., Sirinathsinghji D.J., Hopkins R., Smith D.W., Heavens R.P., Dawson G.R., Boyce S., Conner M.W., Stevens K.A., Slunt H.H., Sisoda S.S., Chen H.Y., Van der Ploeg L.H. beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995, 81:525-531.
72. Zheng H., Koo E.H. Biology and pathophysiology of the amyloid precursor protein. Mol. Neurodegener 2011, 6:27.